Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis

J. S Hill Gaston, Robert D. Inman, Edward T. Ryan, Malabi M. Venkatesan, Eileen M. Barry, Thomas L. Hale, Louis Bourgeois, Richard I. Walker

Research output: Contribution to journalArticle

Abstract

Shigellosis is a major cause of morbidity and mortality among children in low-resource countries. Promising vaccine strategies in development include genetically attenuated Shigella, killed whole cell vaccines, subcellular vaccines, and O-polysaccharide-protein conjugates. There is a concern that Shigella vaccines could either induce reactive arthritis or could prime vaccinees for arthritis after a subsequent exposure to the pathogen because shigellosis is associated with reactive arthritis, especially in patients expressing the HLA B27 histocompatibility antigen. Our understanding of the pathogenesis of reactive arthritis is incomplete, and even surrogate biomarkers of bacterial arthritogenic activity have not yet been identified. Nonetheless, all of the Shigella vaccine strategies currently in development are designed to limit inflammation and intracellular antigen persistence that could trigger arthritogenic sequelae. The relatively low occurrence of the HLA B27 phenotype in most Shigella endemic areas, and the rarity of reported reactive arthritis in these populations, suggests that vaccination with attenuated, killed, or subcellular vaccines may not increase the background incidence of arthritic sequelae. More importantly, incidence rates of shigellosis in children living in low-resource countries suggest that, during maturation, the entire pediatric population may be infected with Shigella-possibly with devastating consequences. Therefore, clinical trials of candidate Shigella vaccines should be pursued aggressively in the developing world, beginning with a Phase 1 in HLA B27-negative volunteers, but proceeding to Phase 2 and Phase 3 in unscreened volunteers. Post-vaccination monitoring for possible reactive arthritis should be included in all clinical protocols.

Original languageEnglish (US)
Pages (from-to)5432-5434
Number of pages3
JournalVaccine
Volume27
Issue number40
DOIs
StatePublished - Sep 4 2009
Externally publishedYes

Fingerprint

Reactive Arthritis
Shigella
arthritis
Shigella Vaccines
Vaccination
Bacillary Dysentery
HLA-B27 Antigen
vaccination
vaccines
shigellosis
Vaccines
Arthritis
Volunteers
complications (disease)
volunteers
Child Mortality
Histocompatibility Antigens
Incidence
histocompatibility antigens
Clinical Protocols

Keywords

  • Reactive arthritis
  • Shigellosis
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Gaston, J. S. H., Inman, R. D., Ryan, E. T., Venkatesan, M. M., Barry, E. M., Hale, T. L., ... Walker, R. I. (2009). Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. Vaccine, 27(40), 5432-5434. https://doi.org/10.1016/j.vaccine.2009.06.107

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. / Gaston, J. S Hill; Inman, Robert D.; Ryan, Edward T.; Venkatesan, Malabi M.; Barry, Eileen M.; Hale, Thomas L.; Bourgeois, Louis; Walker, Richard I.

In: Vaccine, Vol. 27, No. 40, 04.09.2009, p. 5432-5434.

Research output: Contribution to journalArticle

Gaston, J. S Hill ; Inman, Robert D. ; Ryan, Edward T. ; Venkatesan, Malabi M. ; Barry, Eileen M. ; Hale, Thomas L. ; Bourgeois, Louis ; Walker, Richard I. / Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. In: Vaccine. 2009 ; Vol. 27, No. 40. pp. 5432-5434.
@article{c789dd4ca0a644a9af9fd18e376fdc11,
title = "Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis",
abstract = "Shigellosis is a major cause of morbidity and mortality among children in low-resource countries. Promising vaccine strategies in development include genetically attenuated Shigella, killed whole cell vaccines, subcellular vaccines, and O-polysaccharide-protein conjugates. There is a concern that Shigella vaccines could either induce reactive arthritis or could prime vaccinees for arthritis after a subsequent exposure to the pathogen because shigellosis is associated with reactive arthritis, especially in patients expressing the HLA B27 histocompatibility antigen. Our understanding of the pathogenesis of reactive arthritis is incomplete, and even surrogate biomarkers of bacterial arthritogenic activity have not yet been identified. Nonetheless, all of the Shigella vaccine strategies currently in development are designed to limit inflammation and intracellular antigen persistence that could trigger arthritogenic sequelae. The relatively low occurrence of the HLA B27 phenotype in most Shigella endemic areas, and the rarity of reported reactive arthritis in these populations, suggests that vaccination with attenuated, killed, or subcellular vaccines may not increase the background incidence of arthritic sequelae. More importantly, incidence rates of shigellosis in children living in low-resource countries suggest that, during maturation, the entire pediatric population may be infected with Shigella-possibly with devastating consequences. Therefore, clinical trials of candidate Shigella vaccines should be pursued aggressively in the developing world, beginning with a Phase 1 in HLA B27-negative volunteers, but proceeding to Phase 2 and Phase 3 in unscreened volunteers. Post-vaccination monitoring for possible reactive arthritis should be included in all clinical protocols.",
keywords = "Reactive arthritis, Shigellosis, Vaccination",
author = "Gaston, {J. S Hill} and Inman, {Robert D.} and Ryan, {Edward T.} and Venkatesan, {Malabi M.} and Barry, {Eileen M.} and Hale, {Thomas L.} and Louis Bourgeois and Walker, {Richard I.}",
year = "2009",
month = "9",
day = "4",
doi = "10.1016/j.vaccine.2009.06.107",
language = "English (US)",
volume = "27",
pages = "5432--5434",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "40",

}

TY - JOUR

T1 - Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis

AU - Gaston, J. S Hill

AU - Inman, Robert D.

AU - Ryan, Edward T.

AU - Venkatesan, Malabi M.

AU - Barry, Eileen M.

AU - Hale, Thomas L.

AU - Bourgeois, Louis

AU - Walker, Richard I.

PY - 2009/9/4

Y1 - 2009/9/4

N2 - Shigellosis is a major cause of morbidity and mortality among children in low-resource countries. Promising vaccine strategies in development include genetically attenuated Shigella, killed whole cell vaccines, subcellular vaccines, and O-polysaccharide-protein conjugates. There is a concern that Shigella vaccines could either induce reactive arthritis or could prime vaccinees for arthritis after a subsequent exposure to the pathogen because shigellosis is associated with reactive arthritis, especially in patients expressing the HLA B27 histocompatibility antigen. Our understanding of the pathogenesis of reactive arthritis is incomplete, and even surrogate biomarkers of bacterial arthritogenic activity have not yet been identified. Nonetheless, all of the Shigella vaccine strategies currently in development are designed to limit inflammation and intracellular antigen persistence that could trigger arthritogenic sequelae. The relatively low occurrence of the HLA B27 phenotype in most Shigella endemic areas, and the rarity of reported reactive arthritis in these populations, suggests that vaccination with attenuated, killed, or subcellular vaccines may not increase the background incidence of arthritic sequelae. More importantly, incidence rates of shigellosis in children living in low-resource countries suggest that, during maturation, the entire pediatric population may be infected with Shigella-possibly with devastating consequences. Therefore, clinical trials of candidate Shigella vaccines should be pursued aggressively in the developing world, beginning with a Phase 1 in HLA B27-negative volunteers, but proceeding to Phase 2 and Phase 3 in unscreened volunteers. Post-vaccination monitoring for possible reactive arthritis should be included in all clinical protocols.

AB - Shigellosis is a major cause of morbidity and mortality among children in low-resource countries. Promising vaccine strategies in development include genetically attenuated Shigella, killed whole cell vaccines, subcellular vaccines, and O-polysaccharide-protein conjugates. There is a concern that Shigella vaccines could either induce reactive arthritis or could prime vaccinees for arthritis after a subsequent exposure to the pathogen because shigellosis is associated with reactive arthritis, especially in patients expressing the HLA B27 histocompatibility antigen. Our understanding of the pathogenesis of reactive arthritis is incomplete, and even surrogate biomarkers of bacterial arthritogenic activity have not yet been identified. Nonetheless, all of the Shigella vaccine strategies currently in development are designed to limit inflammation and intracellular antigen persistence that could trigger arthritogenic sequelae. The relatively low occurrence of the HLA B27 phenotype in most Shigella endemic areas, and the rarity of reported reactive arthritis in these populations, suggests that vaccination with attenuated, killed, or subcellular vaccines may not increase the background incidence of arthritic sequelae. More importantly, incidence rates of shigellosis in children living in low-resource countries suggest that, during maturation, the entire pediatric population may be infected with Shigella-possibly with devastating consequences. Therefore, clinical trials of candidate Shigella vaccines should be pursued aggressively in the developing world, beginning with a Phase 1 in HLA B27-negative volunteers, but proceeding to Phase 2 and Phase 3 in unscreened volunteers. Post-vaccination monitoring for possible reactive arthritis should be included in all clinical protocols.

KW - Reactive arthritis

KW - Shigellosis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=68349131614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349131614&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.06.107

DO - 10.1016/j.vaccine.2009.06.107

M3 - Article

C2 - 19643213

AN - SCOPUS:68349131614

VL - 27

SP - 5432

EP - 5434

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 40

ER -